NCT04982172View on ClinicalTrials.gov

Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

November 1, 2022

Study Completion Date

February 1, 2023

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Infliximab

Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered

DRUG

Infliximab

Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered

Trial Locations (1)

3000

UZ Leuven, Leuven

All Listed Sponsors
collaborator

KU Leuven

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER